Fluence Partners With Dutch Research Organization Innexo BV to Support Better Access to Cannabis Research
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today an extension of its research partnership with Dutch organization Innexo BV (Innexo), a specialty agricultural contract research organization (CRO) that focuses on molecular farming and medicinal plants.
Innexo is leveraging Fluence’s VYPR Broad R4 LED solution to support its new Acceleration Platform for Innovation (API) program. API empowers innovative, small-scale companies adjacent to the cannabis industry to perform research in medical cannabis cultivation. API’s first round of participants, which include companies like biostimulant and fertilizer producers, will conduct research trials that focus on plant health, strength and resilience beneath Fluence LEDs.
“Fluence is the natural choice for a lighting provider to support API because we share a common vision to make research accessible and drive technological innovations that unlock the future of medical cannabis cultivation,” said Dominique van Gruisen, managing director of Innexo. “Fluence’s science-backed product development and in-house team of horticultural experts is unique among lighting providers. The insight and guidance API participants will receive from subject matter experts at Innexo and Fluence will accelerate their ability to build intellectual property through these research trials.”
Innexo and Fluence’s research collaboration started in October 2022. The companies, which are both recognized as innovators in cannabis research, first came together to investigate the effects of intra-canopy lighting versus top lighting applications in medical cannabis plants.
“The milestones we’re experiencing in the legalization of cannabis in Europe, such as cannabis clubs for cultivation in Germany and the Dutch coffee shop tender, demonstrate significant opportunities and demand for the expansion of cannabis cultivation knowledge,” said Timo Bongartz, general manager of Europe, Middle East and Africa at Fluence. “An increase in research questions has naturally accompanied the expansion of the legal market but is not always backed by the proper resources for exploration. Partnering with a cannabis research trailblazer like Dominique provides the opportunity to facilitate important access to tools that further innovation at Innexo BV.”
Fluence will continue its commitment to furthering cannabis research to help the world grow smarter at GreenTech Amsterdam 2023, one of the largest cannabis industry events in the world. Fluence’s GreenTech booth will host a series of research sessions, featuring Dominique van Gruisen and Fluence experts Dr. David Hawley, principal scientist, and Sebastian Olschowski, research project manager for EMEA.
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About Innexo BV
Innexo BV is a specialty agricultural contract research organization (CRO) based in the Netherlands. The focus and expertise of the company are in medicinal plants, such as cannabis and molecular farming in general. Innexo BV is part of the Botany Group of companies. To learn more about Innexo BV, visit botanygroup.nl/en/innexo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005301/en/
Contact information
For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 160 93335045
For North America,
Callie Neatherlin
callie@redfancommunications.com
512-439-9720
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 14:47:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting me
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 12:15:00 EET | Press release
Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassado
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release
3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad
Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 08:00:00 EET | Press release
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom